Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2431958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126588116074496 |
|---|---|
| author | Shuiqing Xu Wenming Chen Yanchen Li |
| author_facet | Shuiqing Xu Wenming Chen Yanchen Li |
| author_sort | Shuiqing Xu |
| collection | DOAJ |
| description | Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.Results The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).Conclusions The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority. |
| format | Article |
| id | doaj-art-9dfe4aa43de444ddaf12f0d8d1dbaf3d |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-9dfe4aa43de444ddaf12f0d8d1dbaf3d2024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2431958Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single centerShuiqing Xu0Wenming Chen1Yanchen Li2Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital, Beijing, People’s Republic of ChinaBeijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaBeijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaObjective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.Results The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).Conclusions The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.https://www.tandfonline.com/doi/10.1080/16078454.2024.2431958Multiple myelomanewly-diagnosedparaskeletal plasmacytomasdaratumumab-baseddaratumumab-freerisk factors |
| spellingShingle | Shuiqing Xu Wenming Chen Yanchen Li Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center Hematology Multiple myeloma newly-diagnosed paraskeletal plasmacytomas daratumumab-based daratumumab-free risk factors |
| title | Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center |
| title_full | Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center |
| title_fullStr | Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center |
| title_full_unstemmed | Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center |
| title_short | Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center |
| title_sort | daratumumab based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas a retrospective study in a single center |
| topic | Multiple myeloma newly-diagnosed paraskeletal plasmacytomas daratumumab-based daratumumab-free risk factors |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2431958 |
| work_keys_str_mv | AT shuiqingxu daratumumabbasedregimenfornewlydiagnosedmultiplemyelomapatientswithparaskeletalplasmacytomasaretrospectivestudyinasinglecenter AT wenmingchen daratumumabbasedregimenfornewlydiagnosedmultiplemyelomapatientswithparaskeletalplasmacytomasaretrospectivestudyinasinglecenter AT yanchenli daratumumabbasedregimenfornewlydiagnosedmultiplemyelomapatientswithparaskeletalplasmacytomasaretrospectivestudyinasinglecenter |